Biomarkers for non-hodgkin lymphomas and uses thereof
AssigneeBritish Columbia Cancer Agency Branch
InventorsRyan D. MORIN, Marco A. MARRA, Andrew J. MUNGALL, Martin HIRST, Maria MENDEZ-LAGO, Randy D. GASCOYNE, Joseph M. CONNORS
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
Claims27
A method comprising testing a sample from a subject for a mutation in one or more biomarkers listed in Table 1 to identify the subject as having a B-cell non-Hodgkin lymphoma (NHL), wherein the presence of the mutation identifies the subject as having B-cell NHL.
(canceled)
(canceled)
(canceled)
-10. (canceled)
-16. (canceled)
-21. (canceled)
A method comprising testing a sample from a subject for a mutation in MYD88 or CD79B or in one or more biomarkers selected from MEF2B, SGK1, GNA13, and TNFRS14, to classify a subject suspected of having B-cell non-Hodgkin lymphoma (NHL), wherein subjects that have a mutation in MYD88 or CD79B are classified as having activated B-cell (ABC) diffuse large B cell lymphoma (DLBCL) or wherein subjects that have a mutation in one or more biomarkers selected from MEF2B, SGK1, GNA13, and TNFRS14 are classified as having germinal centre B-cell (GCB) diffuse large B cell lymphoma (DLBCL).
A method of monitoring a subject with B cell non-Hodgkin lymphoma (NHL) comprising testing a first sample from the subject for a mutation in one or more biomarkers listed in Table 1 and comparing the results to a control.
(canceled)
Dependencies are inferred from the claim text.